Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005597 | 0.91 | AGTR1 (0.37) | AGTR1AGTR2 | |
| SCHEMBL9739932 | 0.88 | CNR2 (0.33) | CNR2AGTR1 | |
| SCHEMBL9552061 | 0.84 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL6005759 | 0.84 | AGTR1 (0.37) | AGTR1AGTR2 | |
| SCHEMBL6007411 | 0.83 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL6008036 | 0.83 | AGTR1 (0.37) | CNR2AGTR1AGTR2 | |
| SCHEMBL9552291 | 0.81 | AGTR1 (0.39) | CNR2AGTR1AGTR2 | |
| SCHEMBL9552133 | 0.81 | P2RY6 (0.30) | CNR2 | |
| SCHEMBL6004672 | 0.81 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL6006876 | 0.81 | AGTR1 (0.42) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121989-A1 | such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | CNR2 819/4885AGTR1 2/4885AGTR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.